CANUCK LAW

Reporting That You're Not Getting Elsewhere (Do Your Own Research To Verify)

APRIL 20, 2020 BY RONNIE

M-132 And International Pharma Research Grants In Canada



Minister of Health Ministre de la Santé

Ottawa, Canada K1A 0K9

Bill Casey, M.P.
Chair
Standing Committee on Health
The House of Commons
Ottawa, Ontario
K1A 0A4

Dear Mr. Casey:

Pursuant to Standing Order 109 of the House of Commons, on behalf of the Government of Canada, I am pleased to respond to the twentieth Report of the Standing Committee on Health entitled *Towards Open Science: Promoting Innovation in Pharmaceutical Research and Development and Access to Affordable Medications Both*

http://www.lobbycanada.gc.ca

HESA Submissions, Evidence, Reports

Submissions Lodged

hesa.Structural.Genomics.Consortium.submission

hesa.Medicines.Patent.Pool.2018

hesa.Doctors.Without.Borders.2018

hesa.Canadian.Institutes.Of.Health.Research.2018

hesa.Fowke.Keith.University.Manitoba.2018

hesa.University.College.London.drug.prices.2018

hesa.Drugs.For.Neglected.Diseases.Initiative.2018

hesa.Moon.Suerie.2018

hesa.Yusuf.Salim.mcmaster

hesa.FIND.tb.alliance.gates.gavi.unitaid

hesa.Vlassoff.Carol.2018

hesa.Universities.Allied.For.Essential.Medecines.2018

hesa.Bruyere.Research.Institute.2018

hesa.Molyneux.David.2018

LINK To Parliamentary Study Main Page

Federally Funded Health Research: M-132

[/video]

For a speech on passing M-132.

The text is below

Motion Text

That the Standing Committee on Health be instructed to undertake a study on ways of increasing benefits to the public resulting from federally funded health research, with the goals of lowering drugs costs and increasing access to medicines, both in Canada and globally; and that the Committee report its findings and recommendations to the House no later than one year from the time this motion is adopted.

Parliamentary Committee Meetings


PARLIAMENT OF CANADA
VISIT PARLIAMENT
HOUSE OF COMMONS
CHAMBRE DES COMMUNES
CANADA
Parliamentary Business
Members
Participate
About the House
HESA COMMITTEE MEETING
Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witness
to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conduc
committee at a sitting.
For an advanced search, use Publication Search tool.
If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.
October 18, 2018
Notice of Meeting
Minutes
Evidence
Meetings (HESA)
User Guide
Skip to Document Navigation
HESA-116 (October 18, 2018)
Explore By:
Committee Members

Dates Of Meetings

Thursday, September 27, 2018

Hesa.2018.September.27.evidence.transcript

Tuesday, October 2, 2018

Hesa.2018.October.2.evidence.transcript

Thursday, October 4, 2018

Hesa.2018.October.4.evidence.transcript

Tuesday, October 16, 2018

Hesa.2018.October.16.evidence.transcript

Thursday, October 18, 2018

Hesa.2018.October.18th.evidence.transcript

Tuesday, October 23, 2018

Hesa.2018.October.23.evidence.transcript

Thursday, October 25, 2018
Hesa.2018.October.25.evidence.transcript

5. Reports Released To The Commons

TOWARDS OPEN SCIENCE: PROMOTING INNOVATION IN PHARMACEUTICAL RESEARCH AND DEVELOPMENT AND ACCESS TO AFFORDABLE MEDICATIONS BOTH IN CANADA AND ABROAD
Report of the Standing Committee on Health
Bill Casey, Chair

In Canada and around the world, there is rising concern that innovative drugs produced by pharmaceutical companies are no longer affordable and are placing increasing strain on health care budgets. Policy makers have begun to examine ways that public funding for pharmaceutical research and development could address this issue. On 8 ***November 2017, the House of Commons adopted Private Members' Business M-132***, which requested that the House of Commons Standing Committee on Health (the Committee) "undertake a study on ways of increasing benefits to the public resulting from federally funded research, with the goals of lowering drug costs and increasing access to medicines, both in Canada and globally."

On 16 and 18 October 2018, the Committee held two meetings as part of this study and heard from a range of witnesses including health researchers, health research funding organizations, patient groups and civil society organizations. Drawing on witness testimony and written submissions, this report examines the role the ***federal government can play in fostering pharmaceutical research and development both in Canada and globally*** to ensure that pharmaceutical drugs are accessible and affordable.

Note: Recommendations can be found starting at page 20 in the 2018 report released to the House of Commons.

HOUSE OF COMMONS STANDING COMMITTEE ON HEALTH CALLS ON THE GOVERNMENT OF CANADA TO FOSTER PHARMACEUTICAL RESEARCH AND DEVELOPMENT BOTH IN CANADA AND GLOBALLY THROUGH OPEN SCIENCE
Ottawa, November 26, 2018 –

Bill Casey, Chair of the House of Commons Standing Committee on Health, presented the Committee's twentieth report today entitled, Towards Open Science: Promoting Innovation in Pharmaceutical Research and Development and Access to Affordable Medications both in Canada and Abroad.

The Committee's study is in response to Member of Parliament Raj Saini's Private Members' Motion M-132, which requested that the Committee, "undertake a study on ways of increasing benefits to the ***public resulting from federally funded research***, with the goals of lowering drug costs and increasing access to medicines, both in Canada and globally."

In presenting the report to the House, Chair Bill Casey highlighted that "in our testimony, we heard loud and clear that ***more needs to be done to strengthen research and innovation in Canada. I thank Mr. Saini for bringing forth M-132***, and for his efforts in ensuring that the Health Committee can hear why Canada must continue to be a leader in this field."

Drawing on witness testimony heard over the course of two meetings held on 16 and 18 October 2018 and on 23 written submissions, the Committee's report examines how increased federal investment in health research, across the continuum from fundamental to clinical research, would support the development of new medicines. However, witnesses also ***emphasized the importance of ensuring that federal funding in pharmaceutical research and development must also result in the creation of drugs that are***

affordable in Canada and abroad. Witnesses suggested that this could be achieved by fostering the creation of innovative models of pharmaceutical research that prioritize open science in both the development of new drugs and the ***repurposing of existing drugs***. Witnesses explained that the Government of Canada could lead the way by developing a framework that sets priorities for pharmaceutical research and development and promotes open science through collaboration and leveraging of funding across governments, universities, health charities and private industry.

The Committee agrees with these findings and has ***included in its report nine recommendations*** that it believes will support the transformation of pharmaceutical research and development in Canada.

The announcement of the press release is here

Recommendation 1

That the Government of Canada ***create a specific funding mechanism for the development of clinical trial research and infrastructure in Canada*** through the Canadian Institutes of Health Research.

.

Recommendation 2

That the Government of Canada ***increase its funding for clinical trial research*** and infrastructure in Canada to 10% of the Canadian Institutes of Health Research's budget to be on par with jurisdictions leading in this area, such as the United Kingdom and the United States.

.

Recommendation 3

That the Government of Canada explore ways to ***incentivize clinical trial research in Canada for pharmaceutical drugs and incentivize and support the production*** of those drugs in Canada at an advantaged price for Canada and provide venture capital for the proponent.

.

Recommendation 4

That the Canadian Institutes of Health Research attach a Global Access Licensing

requirement to recipients of its research funding that wish to commercialize their research findings.

.

Recommendation 5

That the Canadian Institutes of Health Research include in its existing research and development programs support for the development of open science models of drug discovery.

.

Recommendation 6

That the Canadian Institutes of Health Research develop a framework for open science that supports collaboration and the leveraging of research funding among different partners in pharmaceutical research and development, including health charities, universities, governments, and private industry.

.

Recommendation 7

That Health Canada develop regulatory incentives for pharmaceutical companies that commit to open access to their research data and affordable prices for their products.

.

Recommendation 8

That the Government of Canada undertake a strategic review of its health-related research funding priorities across departments and agencies to enhance coordination, including Health Canada, Public Health Agency of Canada, Canadian Institutes of Health Research, Global Affairs Canada, and Innovation, Science and Economic Development Canada.

.

Recommendation 9

That the Government of Canada explore the feasibility of the public manufacturing of generic medicines.

In the follow-up report, the recommendations were formally adopted.

REPORTS TO PARLIAMENT
hesa.november.2018.report.to.parliament
hesa.government.response.march.2019

Committee Members

As provided by the report, these are the names and ranks of the Committee.

STANDING COMMITTEE ON HEALTH

CHAIR

- Bill Casey

VICE-CHAIRS

- Marilyn Gladu (lobbied by GAVI)
- Don Davies

MEMBERS

- Ramez Ayoub
- Doug Eyolfson
- Raj Grewal
- Ben Lobb
- Ron McKinnon
- John Oliver (Parliamentary Secretary — Non-Voting Member)
- Sonia Sidhu
- Len Webber

OTHER MEMBERS OF PARLIAMENT WHO PARTICIPATED

- Randy Boissonnault
- Terry Duguid
- Randy Hoback
- Tom Kmiec
- Christine Moore
- Raj Saini (lobbied by GAVI)
- Dave Van Kesteren

CLERK OF THE COMMITTEE

- Marie-Hélène Sauvé

Why is the list of the Committee Members here? Well, once you see who some of the connections are, it will likely make the report findings a lot more suspicious.

Committee Members & Pharma Lobbying

Merck Canada Inc.
Consultant: **Danielle Peters, Magnet Strategy Group**
Designated Public Office Holders:
- **Bill Casey**, Member of Parliament | House of Commons
- **Ron McKinnon**, Member of Parliament | House of Commons
- **Travis Warren**, Policy Advisor | Health Canada (HC)

Communication Date: **2019-05-16**

GlaxoSmithKline
In-house Corporation
Designated Public Office Holders:
- **Bill Casey**, Member of Parliament for Cumberland—Colchester | House

Communication Date: **2019-05-16**

RAREi - The Canadian Forum for Rare Disease Innovators / i-RARE: Forum canadien des innovateurs concernant les maladies rares

Consultant: **Rachael Manion, 3Sixty Public Affairs**

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons
- **Ben Lobb**, Member of Parliament & Member of HESA | House of Commons
- **Ramez Ayoub**, Member of Parliament & Member of HESA | House of Commons
- **Bill Casey**, Member of Parliament & Chair of HESA | House of Commons
- **Sonia Sidhu**, Member of Parliament & Member of HESA | House of Commons
- **John Oliver**, Member of Parliament & Parliamentary Secretary to the Minister of Health | House of Commons
- **Doug Eyolfson**, Member of Parliament & Member of HESA | House of Commons
- **Ron McKinnon**, Member of Parliament & Member of HESA | House of Commons
- **Raj Grewal**, Member of Parliament & Member of HESA | House of Commons
- **Len Webber**, Member of Parliament & Member of HESA | House of Commons
- **Marilyn Gladu**, Member of Parliament & Member of HESA | House of Commons

Communication Date: **2018-11-02**

Merck Canada Inc.

Consultant: **Danielle Peters, Magnet Strategy Group**

Designated Public Office Holders:

- **Ron McKinnon**, Member of Parliament | House of Commons
- **Bob Bratina**, Member of Parliament | House of Commons
- **John Oliver**, Member of Parliament | House of Commons
- **Bill Casey**, Member of Parliament | House of Commons
- **Hilary Travis**, Policy Advisor | Innovation, Science and Economic
- **Kate Moussouni**, Senior Policy Advisor | Health Canada (HC)

Communication Date: **2018-10-30**

Hoffmann-La Roche Limited

In-house Corporation

Designated Public Office Holders:

- **David Boudreau**, Executive Director, Medical Devices Bureau (Anti-Microbial Industry Co Day) | Health Canada (HC)
- **Celia Lourenco**, Senior Director, Medical Devices Bureau (Anti-Microbial Industry Coalitic | Health Canada (HC)
- **Hilary Travis**, Policy Advisor, Office of the Minister (Anti-Microbial Industry Coalition Advo Innovation, Science and Economic Development Canada (ISED)
- **John Oliver**, Member of Parliament, (Anti-Microbial Industry Coalition Advocacy Day) | Hc
- **Bill Casey**, Member of Parliament, (Anti-Microbial Industry Coalition Advocacy Day) | Hou
- **Ron McKinnon**, Member of Parliament, (Anti-Microbial Industry Coalition Advocacy Day) Commons
- **Bob Bratina**, Member of Parliament, (Anti-Microbial Industry Coalition Advocacy Day) | H

Communication Date: **2018-10-30**

CANADIAN CANCER SOCIETY / Société canadienne du cancer

In-house Organization

Designated Public Office Holders:

- **Bill Casey**, Member of Parliament, Member of the House of Commons | Hou

Communication Date: **2018-09-27**

DNA Labs Canada

Consultant: **DONALD GRACEY, CG Management and Communications**

Designated Public Office Holders:

- **Don Davis**, MP, NDP | House of Commons
- **Bill Casey**, MP, Liberal Party of Canada | House of Commons
- **Marilyn Gladu**, MP, PC party of Canada | House of Commons

Communication Date: **2018-09-07**

Monthly Communication Report

365818-467191

Registrant name:	BRAD LAVIGNE
Client:	**Emergent BioSolutions Canada Inc.**
Associated registration:	780930-365818-1
Communication date:	2020-03-09
Posted date:	2020-04-15
Designated Public Office Holders who participated in the communication:	**Ryan Hurley**, Parliament Assistant to Don Davies House of Commons **Don Davies**, Member of Parliament House of Commons

Emergent BioSolutions Canada Inc.
Consultant: **BRAD LAVIGNE, Counsel Public Affairs Inc.**
Designated Public Office Holders:
- **Don Davies**, Member of Parliament | House of Commons
- **Ryan Hurley**, Parliament Assistant to Don Davies | House of Commons

Communication Date: **2020-03-09**

Ferrero Canada Ltd.
Consultant: **Jacques J.M. Shore, Gowling WLG (Canada) LLP**
Designated Public Office Holders:
- **Don Davies**, Member of Parliament | House of Commons
- **Peter Farrell**, Legislative Assistant - Don Davies | House of Commons

Communication Date: **2018-03-01**

AbbVie Corporation

In-house Corporation

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons

Communication Date: **2016-06-01**

Innovative Medicines Canada / Médicaments novateurs

In-house Organization

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons

Communication Date: **2016-06-01**

Teva Canada Limited / Teva Canada Limitee

In-house Corporation

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons
- **Deborah Schulte**, Member of Parliament | House of Commons
- **Hursh Jaswal**, Special Assistant | Immigration, Refugees and Citizenship Canada (IRCC
- **Lindsay Hunter**, Ontario Regional Desk & Policy Advisor | Prime Minister's Office (PMO)
- **Jamie Kippen**, Ontario Regional Desk & Policy Advisor | Prime Minister's Office (PMO)
- **Dev Saxena**, Senior Policy Advisor | Innovation, Science and Economic Development Ca
- **David McFarlane**, Director of Policy | Innovation, Science and Economic Development C
- **Kathryn Nowers**, Policy Advisor / Conseillère en politiques | Health Canada (HC)
- **Len Webber**, Member of Parliament | House of Commons
- **Terence Scheltema**, Member's Assistant | House of Commons
- **Bill Casey**, Member of Parliament | House of Commons

Communication Date: **2016-05-12**

Doctors Without Borders Canada / Médecins Sans Frontières (MSF) Canad

Consultant: **Jason Nickerson, Lodestar Public Health Consulting, Inc.**

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons

Communication Date: **2016-05-10**

Research Canada: An Alliance for Health Discovery / Recherche Canada : U pour les découvertes en santé

In-house Organization

Designated Public Office Holders:

- **Dr. Robert Kitchen**, MP | House of Commons
- **Bill Casey**, MP | House of Commons
- **Christine Moore**, MP | House of Commons
- **Gord Brown**, MP | House of Commons
- **Wayne Easter**, MP | House of Commons
- **Nicola Di Iorio**, MP | House of Commons

RESULTS Canada / RESULTATS Canada

In-house Organization

Designated Public Office Holders:

- **Don Davies**, Member of Parliament-Vancouver Kingsway | House of Commons
- **Christine Moore**, Member of Parliament-Abitibi—Témiscamingue | House of Com
- **Alexandra Mendès**, Member of Parliament-Brossard—Saint-Lambert | House of
- **Mobina Jaffer**, Senator | Senate of Canada

Communication Date: **2016-04-13**

Purdue Pharma

Consultant: **MARK RESNICK, THE ROTHWELL GROUP INC.**

Designated Public Office Holders:

- **Don Davies**, MP | House of Commons

Communication Date: **2016-04-06**

Purdue Pharma

Consultant: **MARK RESNICK, THE ROTHWELL GROUP INC.**

Designated Public Office Holders:

- **Don Davies**, MP | House of Commons

Communication Date: **2016-02-02**

PURDUE PHARMA

In-house Corporation

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons

Communication Date: **2016-02-02**

Janssen Inc. (Pharmaceutical Companies of Johnson & Johnson)

In-house Corporation

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons

Communication Date: **2015-05-27**

Canadian Meat Council / Conseil des Viandes du Canada

In-house Organization

Designated Public Office Holders:

- **Don Davies**, Member of Parliament | House of Commons

Communication Date: **2015-05-27**

MININGWATCH CANADA

NOVA Chemicals Corporation

In-house Corporation

Designated Public Office Holders:

- **Filomena Tassi**, MP Minister of Labour | Employment and Social Development Canada (ESDC)
- **Marc Garneau**, Minister of Transport | Transport Canada (TC)
- **Navdeep Bains**, Minister of Innovation, Science and Industry | Innovation, Science and Economic Development Canada (ISED)
- **Melanie Joly**, Minister of Economic Development | Federal Economic Development Agency for Southern Ontario (FedDev)
- **Blaine Calkins**, MP Red Deer-Lacombe | House of Commons
- **Marilyn Gladu**, MP Sarnia-Lambton | House of Commons

Communication Date: **2019-11-20**

AgMedica BioScience Inc.

Consultant: **Marc Kealey, Kealey & Associates Inc**

Designated Public Office Holders:

- **Marilyn Gladu**, Member of Parliament | House of Commons

Communication Date: **2019-07-29**

Merck Canada Inc.

Consultant: **Jennifer Babcock, Crestview Strategy**

Designated Public Office Holders:

- **Dan Albas**, Member of Parliament | House of Commons
- **Alice Wong**, Member of Parliament | House of Commons
- **Marilyn Gladu**, Member of Parliament | House of Commons
- **Karina Rolland**, Manager, Stakeholder Relations | House of Commons
- **Nik Zylstra**, Policy Advisor | House of Commons

Communication Date: **2019-06-05**

Merck Canada Inc.

In-house Corporation

Designated Public Office Holders:

- **Marilyn Gladu**, Member of Parliament, Conservative Party | House of Commons
- **Alice Wong**, Member of Parliament, Conservative Party: Indigeneous and Northern Affairs Canada of Commons
- **Dan Albas**, Member of Parliament, Conservative Party | House of Commons

Communication Date: **2019-06-05**

The above screenshots came from information provided in the Office of the Lobbying Commissioner of Canada. These are far from exhaustive, but show a snapshot at the lobbying that is going on in Canada. Members of this Parliamentary Committee are being lobbied by various drug companies. It's not difficult to see that this is done in order to influence them.

Conflict Of Interest Here

The same committee members who are recommending that Canada undertake more research for pharmaceuticals are the same ones who are being lobbied by pharmaceutical companies. It's not difficult to piece it together.

DRUGS/ALCOHOL, GLOBALISM, HUMAN RIGHTS, LOBBYING, UN/WHO, VACCINES, VOTING PROCESS